Company / Capital Expenditures
Regeneron Pharmaceuticals Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$898.4M
FY2025
5-year range
$429.6M / $898.4M
FY2021-FY2025
Trend
+18.9%
vs FY2024
Sector context
#7 of 194
Health Care
What the data says
Among 194 Health Care companies, Regeneron Pharmaceuticals is in the top 4% for capital expenditures. Capital Expenditures has increased for 5 consecutive years, from $383M in FY2020 to $898M in FY2025.
Based on SEC 10-K filings.
$898M in FY2025 with a 5-year CAGR of +18.6%. Top quartile in the Health Care sector.
Improved from $719M to $898M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +13.5%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
+664.5% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's capital expenditures has grown for 5 consecutive years.
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, capital expenditures increased 18.9% year-over-year.
- Ranks #7 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $898.4M | +18.9% |
| FY2024 | $755.9M | +5.2% |
| FY2023 | $718.6M | +16.9% |
| FY2022 | $614.6M | +43.1% |
| FY2021 | $429.6M | +12.1% |
| FY2020 | $383.1M | -10.8% |
| FY2019 | $429.6M | +12.1% |
| FY2018 | $383.1M | +40.5% |
| FY2017 | $272.6M | -46.7% |
| FY2016 | $511.9M | -24.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026